8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acid

04/01/2021 - "Bempedoic acid represents an effective and safe new therapeutic option in hypercholesterolemia management. "
12/01/2023 - "Bempedoic acid (BA), an ACLY inhibitor commonly used for managing hypercholesterolemia, has shown promising results in addressing hepatic steatosis. "
01/01/2022 - "A Mendelian randomization study has anticipated a protective cardiovascular effect of bempedoic acid; a randomized clinical trial is currently assessing whether the pharmacological control of hypercholesterolemia with bempedoic acid translates into a clinical benefit. "
01/01/2021 - "We included randomized controlled trials that compared the efficacy and safety of bempedoic acid with placebo in patients with hypercholesterolemia. "
01/01/2021 - "Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials."

06/01/2023 - "The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials."
05/01/2023 - "Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials."
11/01/2023 - "Bempedoic acid has shown noteworthy progress in the prevention and management of atherosclerotic cardiovascular disease (ASCVD) in recent years. "
04/13/2023 - "Bempedoic Acid and the Prevention of Cardiovascular Disease."
08/01/2022 - "Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease."

01/01/2021 - "Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside."
01/01/2022 - "Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)."
06/01/2021 - "Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia."
07/01/2021 - "The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD."
01/01/2021 - "With the new FDA approval, bempedoic acid may offer an effective therapy for reducing low-density lipoprotein cholesterol in patients at high risk for cardiovascular events due to established ASCVD or heterozygous familial hypercholesterolemia."

01/01/2021 - "Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia."
12/01/2020 - "Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. "
12/01/2022 - "Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis."
01/01/2021 - "Available evidence from randomized controlled trials suggests that bempedoic acid provides a well-tolerated and effective therapeutic option for lipid lowering in patients with hyperlipidemia."
12/01/2021 - "A meta-analysis demonstrated that bempedoic acid provides a well-tolerated and effective therapeutic option for lipid lowering in patients with hyperlipidemia, both as monotherapy and in combination with various other lipid-lowering agents. "

01/01/2021 - "Bempedoic acid treatment resulted in inhibition of body weight gain and improved the glycemic control. "
01/01/2017 - "APPROACH AND RESULTS: Ldlr-/- mice were fed a high-fat, high-cholesterol diet (42% kcal fat, 0.2% cholesterol) supplemented with bempedoic acid at 0, 3, 10 and 30 mg/kg body weight/day. "
08/01/2014 - "In seven Phase 1 and Phase 2a clinical studies, ETC-1002 dosed once daily for 2-12 weeks has lowered LDL-C and reduced high-sensitivity C-reactive protein by up to 40%, with neutral to positive effects on glucose levels, blood pressure, and body weight. "
01/01/2013 - "Consistent with these mechanisms, ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity. "
01/01/2021 - "Overall, Bempedoic acid alleviated HFD induced Non-Alcoholic Steatohepatitis through inhibition of body weight gain, improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes, and improvement in NAS score. "